Your session is about to expire
← Back to Search
Flavanol
Cocoa Flavanols for Memory Loss
N/A
Waitlist Available
Led By Richard P. Sloan, PhD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age between 50 and 69 years, both inclusive
Healthy Male or Female subjects. (Females must be post-menopausal)
Must not have
Uncomfortable completing memory and attention tasks in the English language
HIV positive status
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Summary
This trial is testing a substance found in cocoa beans to see if it can help improve brain health and thinking abilities in healthy people aged 50-69. Participants will take the cocoa substance for a few months. The study will also look at how inflammation might play a role in these effects. Cocoa products rich in flavonoids have been shown to significantly reduce blood pressure in several studies.
Who is the study for?
This trial is for healthy individuals aged 50-69, with a BMI of 18.0-35 kg/m². Participants must be able to consent, post-menopausal if female, and not have significant health issues or allergies. They shouldn't be on unusual diets, hormone therapies, pregnant/lactating recently, or using certain medications.
What is being tested?
The study tests the effects of cocoa-derived flavanols (650 mg) versus a placebo on brain function and inflammation over 12 weeks in older adults. It's randomized and controlled: participants don't choose which group they're in.
What are the potential side effects?
Potential side effects are not specified but may include typical reactions to dietary supplements such as digestive discomfort or allergic reactions for those sensitive to cocoa products.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 50 and 69 years old.
Select...
I am a healthy individual. If female, I am post-menopausal.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not comfortable doing memory or attention tasks in English.
Select...
I am HIV positive.
Select...
I have Sickle Cell Disease.
Select...
I have had asthma symptoms in the last 3 years.
Select...
I took my medication as instructed during the two-week trial period.
Select...
I have metal fragments in my eye.
Select...
I have a heart condition.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
HMGB1
Secondary study objectives
NFkB
TNFa
Other study objectives
ModBent
ModRey
multiple cognitive domains
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: 650 mg of Cocoapro flavanolsActive Control1 Intervention
Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
Group II: 0mg Cocoapro flavanolsPlacebo Group1 Intervention
Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for inflammation often include antioxidants and anti-inflammatory agents. Antioxidants, such as cocoa-derived dietary flavanols, work by neutralizing free radicals, thereby reducing oxidative stress and preventing cellular damage.
Anti-inflammatory agents, including nonsteroidal anti-inflammatory drugs (NSAIDs) and certain dietary components like omega-3 fatty acids, inhibit pathways that lead to the production of pro-inflammatory molecules like prostaglandins and cytokines. These mechanisms are crucial for inflammation patients as they help to reduce chronic inflammation, alleviate pain, and prevent tissue damage, ultimately improving overall health and quality of life.
Find a Location
Who is running the clinical trial?
Columbia UniversityLead Sponsor
1,498 Previous Clinical Trials
2,766,866 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,804 Previous Clinical Trials
28,194,640 Total Patients Enrolled
New York State Psychiatric InstituteLead Sponsor
479 Previous Clinical Trials
153,571 Total Patients Enrolled
Richard P. Sloan, PhDPrincipal InvestigatorColumbia University
2 Previous Clinical Trials
299 Total Patients Enrolled